Trending

HIV

HIV drug cuts viral load, boosts immunity in Yale study

HIV drug cuts viral load, boosts immunity in Yale study

A Yale University study has found ibalizumab reduced viral replication and increased the count of immune cells in

X

HIV drug cuts viral load, boosts immunity in Yale study

https://pharmaphorum.com/news/ibalizumab-cuts-hiv-viral-load/

GSK’s monthly HIV treatment breakthrough

GSK’s monthly HIV treatment breakthrough

GlaxoSmithKline has seen positive clinical results from the phase 3 study of its once-monthly injectable HIV treatment, stepping

X

GSK’s monthly HIV treatment breakthrough

https://pharmaphorum.com/news/gsks-monthly-hiv-treatment-breakthrough/

ViiV prepares another two-drug HIV filing

ViiV prepares another two-drug HIV filing

ViiV Healthcare says it is on course to change standard care in HIV treatment by providing another combination

X

ViiV prepares another two-drug HIV filing

https://pharmaphorum.com/news/viiv-prepares-another-two-drug-hiv-filing/

FDA approves Janssen’s HIV combination Symtuza

FDA approves Janssen’s HIV combination Symtuza

Janssen has won US approval for its once-daily HIV pill Symtuza (D/C/F/TAF), which it hopes will improve patient

X

FDA approves Janssen’s HIV combination Symtuza

https://pharmaphorum.com/news/fda-janssen-hiv-symtuza/

Study indicates potential breakthrough HIV drug

Study indicates potential breakthrough HIV drug

French biotech Abivax might be on the verge of HIV cure and prevention discovery, after achieving a significant

X

Study indicates potential breakthrough HIV drug

https://pharmaphorum.com/news/study-indicates-breakthrough-hiv/

GSK’s blockbuster HIV drug linked with birth defects

GSK’s blockbuster HIV drug linked with birth defects

Regulators issue warning after preliminary study findings

X

GSK’s blockbuster HIV drug linked with birth defects

https://pharmaphorum.com/news/gsk-blockbuster-hiv-drug-linked-with-birth-defects/

ViiV’s HIV drug could be used for TB co-infection patients

ViiV’s HIV drug could be used for TB co-infection patients

Interim results suggest new treatment option for patients with TB and HIV

X

ViiV’s HIV drug could be used for TB co-infection patients

https://pharmaphorum.com/news/viivs-tivicay-used-hiv-patients-tb-study/

Gilead takes ‘HIV eradication’ combo into clinic

Gilead takes ‘HIV eradication’ combo into clinic

New approach tackles reserve of HIV within the body

X

Gilead takes ‘HIV eradication’ combo into clinic

https://pharmaphorum.com/news/gilead-takes-hiv-eradication-combo-clinic/

GSK’s newly approved HIV treatment Juluca expected to dominate

GSK’s newly approved HIV treatment Juluca expected to dominate

The FDA has approved an HIV dual therapy developed by GSK’s specialist joint venture, ViiV Healthcare, a convenient

X

GSK’s newly approved HIV treatment Juluca expected to dominate

https://pharmaphorum.com/news/fda-approves-gsks-hiv-dual-therapy/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com